PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS - BASE CONTRACT. PERIOD OF PERFORMANCE: 1/25/2019 - 1/24/2024

Sri International, Menlo Park CA

Investigators

Abstract

The purpose of this task order is to hold an orientation/kickoff meeting to discuss Standard Operating Procedures (SOP) for all Contractors awarded an Indefinite Delivery, Indefinite Quantity (ID/IQ) contract for the PREVENT Cancer Preclinical Drug Development Program.